BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taugner J, Eze C, Käsmann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol 2020;15:148. [PMID: 32517716 DOI: 10.1186/s13014-020-01590-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Taugner J, Käsmann L, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers (Basel) 2021;13:1613. [PMID: 33807324 DOI: 10.3390/cancers13071613] [Reference Citation Analysis]
2 Taugner J, Käsmann L, Eze C, Rühle A, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs 2021;39:1189-96. [PMID: 33704621 DOI: 10.1007/s10637-021-01091-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Taugner J, Käsmann L, Karin M, Eze C, Flörsch B, Guggenberger J, Li M, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. Invest New Drugs 2021. [PMID: 34351518 DOI: 10.1007/s10637-021-01143-0] [Reference Citation Analysis]